Intact IGF-binding protein-4 and -5 and their respective fragments isolated from chronic renal failure serum differentially modulate IGF-I actions in cultured growth plate chondrocytes.
Impairment of longitudinal growth among children with chronic renal failure (CRF) may be partly attributable to the inhibition of insulin-like growth factor (IGF) activity by an excess amount of high-affinity IGF-binding proteins (IGFBP). Elevated levels of immunoreactive IGFBP-4 in CRF serum are inversely correlated with the standardized heights of these children, whereas levels of IGFBP-5, which circulates mainly as proteolyzed fragments, are positively correlated with growth parameters. To delineate the respective effects of these IGFBP on growth cartilage, the biologic effects of intact and fragmented forms of IGFBP-4 and IGFBP-5 on rat growth plate chondrocytes in primary cultures were characterized. Intact IGFBP-4 and IGFBP-5 and the amino-terminal fragment IGFBP-5(1-169) were recombinant proteins; the carboxy-terminal fragments IGFBP-5(144-252) and IGFBP-4(136-237) and the amino-terminal fragment IGFBP-4(1-122) were purified to homogeneity from CRF hemofiltrates. Intact IGFBP-4 and, to a lesser extent, IGFBP-4(1-122) inhibited IGF-I-induced cell proliferation. In contrast, intact IGFBP-5 was stimulatory in the absence or presence of exogenous IGF-I, whereas the amino-terminal fragment IGFBP-5(1-169) was inhibitory. Studies on the mechanism by which IGFBP-4 and IGFBP-5 exert opposite effects on chondrocyte proliferation demonstrated that intact IGFBP-4 prevented the binding of (125)I-IGF-I to chondrocytes, whereas intact IGFBP-5 enhanced ligand binding and was able to bind specifically to the cell membrane. These data suggest that intact IGFBP-4 and, to a lesser extent, IGFBP-4(1-122) act exclusively as growth-inhibitory binding proteins in the growth cartilage. IGFBP-5, however, can either stimulate (if it remains intact) or inhibit (if amino-terminal forms predominate) IGF-I-stimulated chondrocyte proliferation.
Kiepe
Daniela
D
Division of Pediatric Nephrology, University Children's Hospital Heidelberg, Heidelberg, Germany.
Andress
Dennis L
DL
Department of Medicine, Veterans Affairs Medical Center and University of Washington, Seattle, Washington.
Mohan
Subburaman
S
J. L. Pettis Veterans Administration Medical Center and Loma Linda University, Loma Linda, California.
Ständker
Ludger
L
Lower Saxony Institute for Peptide Research, Hannover, Germany.
Ulinski
Tim
T
Division of Pediatric Nephrology, University Children's Hospital Heidelberg, Heidelberg, Germany.
Himmele
Rainer
R
Division of Pediatric Nephrology, University Children's Hospital Heidelberg, Heidelberg, Germany.
Mehls
Otto
O
Division of Pediatric Nephrology, University Children's Hospital Heidelberg, Heidelberg, Germany.
Tönshoff
Burkhard
B
Division of Pediatric Nephrology, University Children's Hospital Heidelberg, Heidelberg, Germany.
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D019902:Chondrocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006132:Growth Plate / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D018974:Insulin-Like Growth Factor Binding Protein 4 / Q000302:isolation & purification* / Q000378:metabolism / Q000494:pharmacology*; D018975:Insulin-Like Growth Factor Binding Protein 5 / Q000302:isolation & purification* / Q000378:metabolism / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism / Q000494:pharmacology*; D007676:Kidney Failure, Chronic / Q000097:blood*; D010446:Peptide Fragments / Q000302:isolation & purification; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017526:Receptor, IGF Type 1 / Q000235:genetics
D018974:Insulin-Like Growth Factor Binding Protein 4; D018975:Insulin-Like Growth Factor Binding Protein 5; D010446:Peptide Fragments; D012333:RNA, Messenger; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1